Company intelligence / Profile preview

Aton Biotech

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Aton Biotech has manufactured over 700 commercial batches and 130 clinical/toxicology batches supporting >30 molecules; audited >90 times; recognized for integrated, high-quality manufacturing and rapid, flexible development for clients pursuing IND/BLA/NDA filings

Therapeutic areas: Other
Modalities: Monoclonal antibodyAntibody-drug conjugateFusion proteinBispecific monoclonal antibodyProteinVaccineEnzyme (biologic)Biosimilar
Industry: Contract Manufacturing Organization

Partnerships

KangaBio (development/manufacturing of prodrugs of immune-stimulating agents and multispecific biologics)

Beyond the preview

Go deeper on Aton Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aton Biotech.

Explore the full profile